Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race
Plus: Japan Pledges Support For Covax Initiative
Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.
You may also be interested in...
Gottlieb: Staged Access To Coronavirus Vaccine Possible Through EUA
Former FDA Commissioner says agency could grant an EUA for a vaccine, but require it meet the standard for full approval, and then roll it out gradually with postmarket data collection.
Coronavirus Notebook: EU Joins COVAX, Sanofi/GSK Vaccine Moves To Phase I/II
Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients.
Analyst Predicts $20bn COVID Vaccines Market In 2021
Analysts have taken a first stab at predicting the size of the COVID-19 vaccine market – in which Pfizer and Moderna are likely to start strong, but could give way to other big players.